Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

14P - High CMTM6 and PD-L1 co-expression predict metastasis and poor prognosis in oesophageal squamous cell carcinoma

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Yuejun Luo

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

Y. Luo1, C. Zhang1, Z. Zhang2, G. Zhang1, L. Xue1

Author affiliations

  • 1 Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing/CN
  • 2 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
More

Resources

Abstract 14P

Background

The newly identified immune checkpoint inhibitor CMTM6 (CKLF-like MARVEL transmembrane domain containing 6) is reported as a critical regulator of programmed death ligand (PD-L1) expression by modulating stability through ubiquitination and modulate T cell expression in several tumors. However, the role of CMTM6 has so far remained unclear in esophageal cancer, especially in esophageal squamous cell carcinoma (ESCCs). The aim of this study was to investigate the expression of CMTM6 and PD-L1 and to confirm their predictive roles in ESCC clinical prognosis.

Methods

We collected 137 ESCCs patients' pretreatment biopsies from multiple centers in China. CMTM6 and PD-L1 immunohistochemical expressions were evaluated. The correlation between CMTM6 and PD-L1 expression was also determined based on immunohistochemistry and RNA-sequencing data obtained from The Cancer Genome Atlas (TCGA) database. The prognostic value (overall survival (OS) and disease-free survival (DFS)) of CMTM6 and PD-L1 were also evaluated.

Results

CMTM6 expression was detected in approximately 70% of ESCCs tumor tissues, and CMTM6 was highly expressed in ESCCs tumor tissues compared to adjacent normal tissues. In addition, PD-L1 expression is always found in CMTM6 positive cases. CMTM6 expression was positively correlated with PD-L1 expression in immunohistochemical data (P<0.05). A positive correlation was also identified in the mRNA expression data (P<0.05). CMTM6 and PD-L1 expression were associated with cancer metastases, but not with patients’ age and gender. In univariate survival analysis found that positive CMTM6 and PD-L1 expression were correlated with poor OS (P<0.05) and inferior DFS (P<0.05). In multivariate survival analysis found that high CMTM6 and PD-L1 co-expression was significantly associated with poor OS (P<0.05) and inferior DFS (P<0.05).

Conclusions

CMTM6 expression is positively associated with PD-L1 expression. High CMTM6 and PD-L1 co-expression correlated with metastasis and predict the poor OS and inferior DFS. Thus, CMTM6 and PD-L1 co-expression can be a promising predictor useful for predicting ESCCs prognosis.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.